Sudeep Pharma IPO: An Analysis
Sudeep Pharma, a company making ingredients for medicines, food, and nutrition, recently held an Initial Public Offering (IPO). Investors showed a strong interest, bidding for 99,01,00,150 shares when the company was offering 1,05,64,926. This means the IPO was heavily subscribed – it received bids 93.72 times higher than the shares available. This indicates considerable confidence in the company’s future.
Key Points
- 93.72 times oversubscribed, indicating strong investor interest.
- QIBs subscribed 213.08 times, Non-Institutional 116.72 times.
- Retail investors subscribed 15.65 times, showing moderate interest.
- IPO closed on November 25, 2025, at a price range of Rs 563-593.
- Raised Rs 268.49 crore from anchor investors before the IPO.
- Company focuses on pharmaceutical, food, and nutrition ingredients.
Different groups of investors reacted differently. Qualified Institutional Buyers (QIBs) – big investment groups – were most interested, subscribing 213.08 times more than offered. Non-Institutional Investors showed a solid interest, subscribing 116.72 times, while Retail Individual Investors were less enthusiastic, subscribing only 15.65 times. This suggests the company is appealing to a range of investors.
The IPO itself was structured with two parts. First, the company offered a new share issue worth up to Rs 95 crore. Second, existing shareholders – Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani, and Avani Sujit Bhayani – were selling 1,34,90,726 shares for up to Rs 800 crore. The price was set between Rs 563 and Rs 593 per share. This money will be used to buy new equipment and for general business purposes.
Sudeep Pharma makes key ingredients – like calcium, zinc, and iron – for companies making medicines, food, and nutritional supplements. They also create specialized mineral systems using technology like encapsulated ingredients and spray-dried formats. In the last quarter, 66.43% of their sales came from the pharmaceutical and food sectors, and 33.57% from their specialty ingredients business. Over half of their sales were made in India (41.32%), while the rest were exported (58.68%).
Before the IPO, the company secured Rs 268.49 crore from 25 anchor investors. This pre-funding helped build excitement and provide a stable starting point. For the quarter ended June 30, 2025, Sudeep Pharma reported a net profit of Rs 30.81 crore and sales of Rs 124.92 crore, demonstrating a solid financial performance.
Investing in Sudeep Pharma shows confidence in the growing demand for specialized ingredients in the food and pharmaceutical industries.
“`
